Who are iv Procainamide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Flecainide controlled release, Oral Capsule Mexiletine (IR), Flecainide Injectable Solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/iv-procainamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

iv Procainamide — Competitive Intelligence Brief

iv Procainamide (iv Procainamide) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Class IA antiarrhythmic agent. Area: Cardiovascular.

marketed Class IA antiarrhythmic agent Cardiac voltage-gated sodium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

iv Procainamide (iv Procainamide) — Hospital General Universitario Gregorio Marañon. Procainamide is a Class IA antiarrhythmic that blocks cardiac sodium channels and slows conduction velocity to suppress abnormal electrical activity in the heart.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
iv Procainamide TARGET	iv Procainamide	Hospital General Universitario Gregorio Marañon	marketed	Class IA antiarrhythmic agent	Cardiac voltage-gated sodium channel
Flecainide controlled release	Flecainide controlled release	MEDA Pharma GmbH & Co. KG	marketed	Class IC antiarrhythmic agent	Cardiac voltage-gated sodium channel (Nav1.5)
Oral Capsule Mexiletine (IR)	Oral Capsule Mexiletine (IR)	Lupin Ltd.	phase 3	Class IB antiarrhythmic agent	Cardiac voltage-gated sodium channel (Nav1.5)
Flecainide Injectable Solution	Flecainide Injectable Solution	Hippocration General Hospital	phase 3	Class IC antiarrhythmic agent	Cardiac voltage-gated sodium channel (Nav1.5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Class IA antiarrhythmic agent class)

Hospital General Universitario Gregorio Marañon · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). iv Procainamide — Competitive Intelligence Brief. https://druglandscape.com/ci/iv-procainamide. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab